|
1
|
Maxwell KN, Soccio RE, Duncan EM, Sehayek
E and Breslow JL: Novel putative SREBP and LXR target genes
identified by microarray analysis in liver of cholesterol-fed mice.
J Lipid Res. 44:2109–2119. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Seidah NG, Benjannet S, Wickham L, et al:
The secretory proprotein convertase neural apoptosis-regulated
convertase 1 (NARC-1): liver regeneration and neuronal
differentiation. Proc Natl Acad Sci USA. 100:928–933. 2003.
View Article : Google Scholar
|
|
3
|
Seidah NG: PCSK9 as a therapeutic target
of dyslipidemia. Expert Opin Ther Targets. 13:19–28. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen JC, Boerwinkle E, Mosley TH Jr and
Hobbs HH: Sequence variations in PCSK9, low LDL, and protection
against coronary heart disease. N Engl J Med. 354:1264–1272. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stein EA, Gipe D, Bergeron J, et al:
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to
reduce low-density lipoprotein cholesterol in patients with
heterozygous familial hypercholesterolaemia on stable statin dose
with or without ezetimibe therapy: a phase 2 randomised controlled
trial. Lancet. 380:29–36. 2012.
|
|
6
|
Hall SS: Genetics: a gene of rare effect.
Nature. 496:152–155. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brown MS and Goldstein JL: Biomedicine.
Lowering LDL - not only how low, but how long? Science.
311:1721–1723. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS
and Liu LS: PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL
via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem.
359:347–358. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang Z, Jiang L, Peng J, et al: PCSK9
siRNA suppresses the inflammatory response induced by oxLDL through
inhibition of NF-κB activation in THP-1-derived macrophages. Int J
Mol Med. 30:931–938. 2012.PubMed/NCBI
|
|
10
|
Sun X, Essalmani R, Day R, Khatib AM,
Seidah NG and Prat A: Proprotein convertase subtilisin/kexin type 9
deficiency reduces melanoma metastasis in liver. Neoplasia.
14:1122–1131. 2012.PubMed/NCBI
|
|
11
|
Poirier S, Prat A, Marcinkiewicz E, et al:
Implication of the proprotein convertase NARC-1/PCSK9 in the
development of the nervous system. J Neurochem. 98:838–850. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Citron M: Alzheimer’s disease: strategies
for disease modification. Nat Rev Drug Discov. 9:387–398. 2010.
|
|
13
|
Cunningham C, Wilcockson DC, Campion S,
Lunnon K and Perry VH: Central and systemic endotoxin challenges
exacerbate the local inflammatory response and increase neuronal
death during chronic neurodegeneration. J Neurosci. 25:9275–9284.
2005. View Article : Google Scholar
|
|
14
|
Verhamme P, Quarck R, Hao H, et al:
Dietary cholesterol withdrawal reduces vascular inflammation and
induces coronary plaque stabilization in miniature pigs. Cardiovasc
Res. 56:135–144. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nematbakhsh M, Haghjooyjavanmard S,
Mahmoodi F and Monajemi AR: The prevention of endothelial
dysfunction through endothelial cell apoptosis inhibition in a
hypercholesterolemic rabbit model: the effect of L-arginine
supplementation. Lipids Health Dis. 7:272008. View Article : Google Scholar
|
|
16
|
Kankaanpaa J, Turunen SP, Moilanen V,
Horkko S and Remes AM: Cerebrospinal fluid antibodies to oxidized
LDL are increased in Alzheimer’s disease. Neurobiol Dis.
33:467–472. 2009.PubMed/NCBI
|
|
17
|
Martins IJ, Berger T, Sharman MJ, Verdile
G, Fuller SJ and Martins RN: Cholesterol metabolism and transport
in the pathogenesis of Alzheimer’s disease. J Neurochem.
111:1275–1308. 2009.
|
|
18
|
Chiang LW, Grenier JM, Ettwiller L, et al:
An orchestrated gene expression component of neuronal programmed
cell death revealed by cDNA array analysis. Proc Natl Acad Sci USA.
98:2814–2819. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bingham B, Shen R, Kotnis S, et al:
Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel
serine proteinase. Cytometry A. 69:1123–1131. 2006.PubMed/NCBI
|
|
20
|
Cameron J, Ranheim T, Kulseth MA, Leren TP
and Berge KE: Berberine decreases PCSK9 expression in HepG2 cells.
Atherosclerosis. 201:266–273. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ji HF and Shen L: Berberine: a potential
multipotent natural product to combat Alzheimer’s disease.
Molecules. 16:6732–6740. 2011.PubMed/NCBI
|
|
22
|
Kysenius K, Muggalla P, Matlik K, Arumae U
and Huttunen HJ: PCSK9 regulates neuronal apoptosis by adjusting
ApoER2 levels and signaling. Cell Mol Life Sci. 69:1903–1916. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ranheim T, Mattingsdal M, Lindvall JM, et
al: Genome-wide expression analysis of cells expressing gain of
function mutant D374Y-PCSK9. J Cell Physiol. 217:459–467. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Di Paolo G and Kim TW: Linking lipids to
Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci.
12:284–296. 2011.
|
|
25
|
Jonas MC, Costantini C and Puglielli L:
PCSK9 is required for the disposal of non-acetylated intermediates
of the nascent membrane protein BACE1. EMBO Rep. 9:916–922. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ko MH and Puglielli L: Two endoplasmic
reticulum (ER)/ER Golgi intermediate compartment-based lysine
acetyltransferases post-translationally regulate BACE1 levels. J
Biol Chem. 284:2482–2492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu M, Wu G, Baysarowich J, et al: PCSK9
is not involved in the degradation of LDL receptors and BACE1 in
the adult mouse brain. J Lipid Res. 51:2611–2618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shibata N, Ohnuma T, Higashi S, et al: No
genetic association between PCSK9 polymorphisms and Alzheimer’s
disease and plasma cholesterol level in Japanese patients.
Psychiatr Genet. 15:2392005.
|
|
29
|
Reynolds CA, Hong MG, Eriksson UK, et al:
Analysis of lipid pathway genes indicates association of sequence
variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. Hum Mol
Genet. 19:2068–2078. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mattson MP and Camandola S: NF-κB in
neuronal plasticity and neurodegenerative disorders. J Clin Invest.
107:247–254. 2001.
|
|
31
|
Sola S, Aranha MM and Rodrigues CM:
Driving apoptosis-relevant proteins toward neural differentiation.
Mol Neurobiol. 46:316–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Culmsee C and Plesnila N: Targeting Bid to
prevent programmed cell death in neurons. Biochem Soc Trans.
34:1334–1340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wong HK, Fricker M, Wyttenbach A, et al:
Mutually exclusive subsets of BH3-only proteins are activated by
the p53 and c-Jun N-terminal kinase/c-Jun signaling pathways during
cortical neuron apoptosis induced by arsenite. Mol Cell Biol.
25:8732–8747. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lindsten T, Zong WX and Thompson CB:
Defining the role of the Bcl-2 family of proteins in the nervous
system. Neuroscientist. 11:10–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Almeida A: Genetic determinants of
neuronal vulnerability to apoptosis. Cell Mol Life Sci. 70:71–88.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gotz R, Karch C, Digby MR, Troppmair J,
Rapp UR and Sendtner M: The neuronal apoptosis inhibitory protein
suppresses neuronal differentiation and apoptosis in PC12 cells.
Hum Mol Genet. 9:2479–2489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baratchi S, Kanwar RK and Kanwar JR:
Survivin: a target from brain cancer to neurodegenerative disease.
Crit Rev Biochem Mol Biol. 45:535–554. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dhandapani KM and Brann DW: Transforming
growth factor-β: a neuroprotective factor in cerebral ischemia.
Cell Biochem Biophys. 39:13–22. 2003.
|
|
39
|
Singh MH, Brooke SM, Zemlyak I and
Sapolsky RM: Evidence for caspase effects on release of cytochrome
c and AIF in a model of ischemia in cortical neurons.
Neurosci Lett. 469:179–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chiou SH, Chen SJ, Peng CH, et al:
Fluoxetine up-regulates expression of cellular FLICE-inhibitory
protein and inhibits LPS-induced apoptosis in hippocampus-derived
neural stem cell. Biochem Biophys Res Commun. 343:391–400. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Broughton BR, Reutens DC and Sobey CG:
Apoptotic mechanisms after cerebral ischemia. Stroke. 40:e331–e339.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Blaise S, Kneib M, Rousseau A, et al: In
vivo evidence that TRAF4 is required for central nervous system
myelin homeostasis. PLoS One. 7:e309172012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
LeBlanc AC: The role of apoptotic pathways
in Alzheimer’s disease neurodegeneration and cell death. Curr
Alzheimer Res. 2:389–402. 2005.
|
|
44
|
Joseph D’Ercole A and Ye P: Expanding the
mind: insulin-like growth factor I and brain development.
Endocrinology. 149:5958–5962. 2008.PubMed/NCBI
|
|
45
|
McCarthy MJ, Rubin LL and Philpott KL:
Involvement of caspases in sympathetic neuron apoptosis. J Cell
Sci. 110(Pt 18): 2165–2173. 1997.PubMed/NCBI
|
|
46
|
Ludwig-Galezowska AH, Flanagan L and Rehm
M: Apoptosis repressor with caspase recruitment domain, a
multifunctional modulator of cell death. J Cell Mol Med.
15:1044–1053. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gora-Kupilas K and Josko J: The
neuroprotective function of vascular endothelial growth factor
(VEGF). Folia Neuropathol. 43:31–39. 2005.PubMed/NCBI
|
|
48
|
Krantic S, Mechawar N, Reix S and Quirion
R: Apoptosis-inducing factor: a matter of neuron life and death.
Prog Neurobiol. 81:179–196. 2007. View Article : Google Scholar : PubMed/NCBI
|
